EXOZ: Invizyne Price to Sales

Brandmark of Invizyne (EXOZ)

The price-to-sales ratio dynamics show that the current parameter equals . High laboratory costs at eXoZymes Inc (EXOZ) create a significant burden prior to the commercialization stage. The efficiency of complex molecule synthesis allows for the reduction of production costs. Meanwhile, the company relies on licensing and cloud computing to develop AI algorithms, outsourcing mass production to external contractors.

EXOZ (Invizyne Technologies, Inc.) Price-to-Revenue Ratio history from 07/04/2022 to 11/13/2026

Invizyne Technologies, Inc. (EXOZ) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart invizyne.com|EXOZ - Analyst Consensus Forecast
- market capitalization information:
Market Value Invizyne Technologies, Inc.|EXOZ - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Equity per Share eXoZymes|EXOZ - Company Book Value|Market-to-Book Ratio invizyne.com|EXOZ - Cumulative Company Assets
- business debt structure and liquidity details:
Aggregate Debt to Equity eXoZymes Inc|EXOZ - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Invizyne|EXOZ - Company Debts|Debt to Book Value Invizyne Technologies, Inc.|EXOZ - Company Long-Term Debts|Short-Term Debt eXoZymes|Interim Coverage Ratio invizyne.com
- net income and valuation multiples indicators:
EXOZ - Net Income|Expected Net Income eXoZymes Inc|EXOZ - P/E Multiple|Market Cap to Projected Earnings Invizyne Technologies|EXOZ - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Invizyne Technologies, Inc.|EXOZ - Operating profit EBITDA|Net earnings per share for the last 12 months eXoZymes|EXOZ - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months invizyne.com|EXOZ - Net earnings per share growth this year|Projected earnings per share growth rate for next year eXoZymes Inc
- total revenue and sales volume data:
EXOZ - Company Revenue|Company Expected Sales Volume invizyne.com|EXOZ - Market Cap to Revenue|Future Price to Revenue Invizyne Technologies, Inc.
Fundamental company analysis:EXOZ (invizyne.com)
Flagship merchandise of eXoZymes

The ratio of market capitalization to annual sales allows for the determination of the premium paid for a business by measuring the company's value through the prism of its actual revenue. By analyzing the price-to-sales ratio dynamics, an investor can assess the resilience of eXoZymes Inc. (EXOZ) to geopolitical risks and sanctions, which restrict access to raw materials and reduce the overall profitability of biocatalyst production.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|Verona Pharma PLC (VRNA) - Price to Sales|MENS: Market Cap to Revenue|LGND (Ligand Corp) - Market Cap to Revenue Ratio|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|Price to Sales perrigo.com (PRGO)|Market Cap to Revenue ALVO|Liquidia Corp - Price-to-Sales Ratio|Market Cap to Revenue GLPG (Galapagos Genomics)|ANIP - Price to Sales|Price-to-Revenue Ratio MannKind Corporation MNKD|AMPH - Market Cap to Revenue|Pacira BioSciences, Inc. - P/S Multiple|Price to Sales ARS Pharmaceuticals Inc|Theravance (TBPH) - Price-to-Revenue Ratio|AQST - Price-to-Revenue Coefficient|Market Cap to Revenue SCPH|TECX: Market Capitalization-to-Revenue Ratio|P/S Multiple TNXP|Price-to-Revenue Coefficient sxtchina.com|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BHST: Market Cap to Revenue Ratio|Oramed Pharma - P/S Multiple|Entera Bio Ltd. (ENTX) - Market Cap to Revenue|HYFT: P/S Multiple|Price to Sales ABVC BioPharma Inc. (ABVC)|Market Cap to Revenue CPIX|Market Cap to Revenue Ratio QNTM (Quantum BioPharma Corp)|Price-to-Revenue Ratio FibroGen, Inc. (FGEN)|TELO - Price to Sales|Rani Therapeutics Holdings, Inc. - Market Cap to Revenue|SNYR (Synergy CHC Corp.) - Price-to-Sales Ratio|RLYB - Price-to-Revenue Ratio|Price-to-Sales Ratio LEXX|PULM: P/S Multiple|Pheton Holdings - Market Capitalization-to-Revenue Ratio|APM (Aptorum Group Ltd) - P/S Multiple|P/S Multiple Lyra Therapeutics Inc.|Price-to-Revenue Ratio Impact BioMedical (IBO)|TNFA (tnfpharma.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio cbdMD YCBD|PRFX - Market Cap to Revenue|Auris Medical - P/S Multiple|LIPO - P/S Multiple|OPTN (Optinose) - Market Cap to Revenue|Pieris Pharma - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Procaps Group S.A.|Price to Sales petrospharma.com PTPI|Market Cap to Revenue QLI (Qilian International Holding)|Market Cap to Sales Volume SLRN|P/S Multiple TFFP (TFF Pharma)